000003496 001__ 3496
000003496 005__ 20180208222108.0
000003496 0247_ $$2pmid$$apmid:20665489
000003496 0247_ $$2DOI$$a10.1007/s00339-009-5188-0
000003496 0247_ $$2WOS$$aWOS:000266372100005
000003496 0247_ $$2ISSN$$a0947-8396
000003496 037__ $$aPreJuSER-3496
000003496 041__ $$aeng
000003496 082__ $$a530
000003496 084__ $$2WoS$$aMaterials Science, Multidisciplinary
000003496 084__ $$2WoS$$aPhysics, Applied
000003496 1001_ $$0P:(DE-Juel1)132115$$aGibbon, P.$$b0$$uFZJ
000003496 245__ $$aModelling and optimisation of femtosecond laser-produced K-alpha sources
000003496 260__ $$aBerlin$$bSpringer$$c2009
000003496 300__ $$a23 - 31
000003496 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000003496 3367_ $$2DataCite$$aOutput Types/Journal article
000003496 3367_ $$00$$2EndNote$$aJournal Article
000003496 3367_ $$2BibTeX$$aARTICLE
000003496 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000003496 3367_ $$2DRIVER$$aarticle
000003496 440_0 $$0560$$aApplied Physics A$$v96$$x0947-8396$$y1
000003496 500__ $$aThis work was supported by the Deutsche Forschungsgemeinschaft (DFG grant-nos. GI 300/3-1, TE 190/6-1 and So 408/6-3) and the FLASH network.
000003496 520__ $$aThe most reliable prognostic factor in colon cancer is the TNM classification. The objective of this study was to assess and compare the prognostic role of tumor-infiltrating lymphocytes (TILs) in stage II colon cancer.Immunohistochemistry was used to assess the density of TILs that were positive for cluster of differentiation 3 (CD3) (T-cell coreceptor), CD45 isoform RO (CD45RO) (protein tyrosine phosphatase), nuclear transcription factor forkhead box P3 (FOXP3), and CD25 (a type I transmembrane protein) according to tumor site (intraepithelial and stromal) in samples from 87 patients who had stage II colon cancer. These variables were evaluated for their association with histopathologic features along with overall survival (OS) and disease-free survival (DFS).Intraepithelial CD3-posititve (CD3+), CD45RO+, CD25+, and FOXP3+ TILs were associated significantly with better DFS (P = .049, P = .009, P = .013, and P = .001, respectively). The estimated 5-year OS rates for patients who had high-density CD45RO+ and FOXP3+ expression was 100% for both compared with 79.2% and 78.8% for patients who had low-density CD45RO+ and FOXP3+ expression (P = .017 and P = .040, respectively). A significant prognostic factor for both OS and DFS was high-density stromal CD45RO+ lymphocytic infiltration (OS: P = .031; relative risk [RR], 0.134; 95% confidence interval [CI], 0.015-1.164; DFS: P = .013; RR, 0.198; 95% CI, 0.055-0.710); whereas intraepithelial FOXP3+ expression was an independent prognostic factor for DFS (P = .032; RR, 0.108; 95% CI, 0.014-0.821).FOXP3+ and CD45RO+ TILs demonstrated independent prognostic significance for survival in the current investigation. These results may help to improve the prognostication of early stage colon cancer. Cancer 2010.
000003496 536__ $$0G:(DE-Juel1)FUEK411$$2G:(DE-HGF)$$aScientific Computing$$cP41$$x0
000003496 588__ $$aDataset connected to Web of Science, Pubmed
000003496 650_2 $$2MeSH$$aAdult
000003496 650_2 $$2MeSH$$aAged
000003496 650_2 $$2MeSH$$aColonic Neoplasms: immunology
000003496 650_2 $$2MeSH$$aColonic Neoplasms: pathology
000003496 650_2 $$2MeSH$$aDisease-Free Survival
000003496 650_2 $$2MeSH$$aFemale
000003496 650_2 $$2MeSH$$aHumans
000003496 650_2 $$2MeSH$$aImmunohistochemistry
000003496 650_2 $$2MeSH$$aLymphocytes, Tumor-Infiltrating: immunology
000003496 650_2 $$2MeSH$$aMale
000003496 650_2 $$2MeSH$$aMiddle Aged
000003496 650_2 $$2MeSH$$aNeoplasm Invasiveness
000003496 650_2 $$2MeSH$$aPrognosis
000003496 650_7 $$2WoSType$$aJ
000003496 7001_ $$0P:(DE-Juel1)VDB84133$$aMasek, M.$$b1$$uFZJ
000003496 7001_ $$0P:(DE-HGF)0$$aTeubner, U.$$b2
000003496 7001_ $$0P:(DE-HGF)0$$aLu, W.$$b3
000003496 7001_ $$0P:(DE-HGF)0$$aNicoul, M.$$b4
000003496 7001_ $$0P:(DE-HGF)0$$aShymanovich, A.$$b5
000003496 7001_ $$0P:(DE-HGF)0$$aTarasevitch, A.$$b6
000003496 7001_ $$0P:(DE-HGF)0$$aZhou, P.$$b7
000003496 7001_ $$0P:(DE-HGF)0$$aSokolowski-Tinten, K.$$b8
000003496 7001_ $$0P:(DE-HGF)0$$avon der Linde, D.$$b9
000003496 773__ $$0PERI:(DE-600)1398311-8$$a10.1007/s00339-009-5188-0$$gVol. 96, p. 23 - 31$$p23 - 31$$q96<23 - 31$$tApplied physics / A$$v96$$x0947-8396$$y2009
000003496 8567_ $$uhttp://dx.doi.org/10.1007/s00339-009-5188-0
000003496 909CO $$ooai:juser.fz-juelich.de:3496$$pVDB
000003496 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000003496 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000003496 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000003496 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000003496 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000003496 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000003496 9141_ $$y2009
000003496 9131_ $$0G:(DE-Juel1)FUEK411$$aDE-HGF$$bSchlüsseltechnologien$$kP41$$lSupercomputing$$vScientific Computing$$x0
000003496 9201_ $$0I:(DE-Juel1)JSC-20090406$$gJSC$$kJSC$$lJülich Supercomputing Centre$$x0
000003496 970__ $$aVDB:(DE-Juel1)109581
000003496 980__ $$aVDB
000003496 980__ $$aConvertedRecord
000003496 980__ $$ajournal
000003496 980__ $$aI:(DE-Juel1)JSC-20090406
000003496 980__ $$aUNRESTRICTED